Aurinia Pharmaceuticals Inc (AUPH)
8.88
+0.11
(+1.25%)
USD |
NASDAQ |
Nov 22, 14:03
Aurinia Pharmaceuticals Revenue (Quarterly): 67.77M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 67.77M |
| June 30, 2024 | 57.19M |
| March 31, 2024 | 50.30M |
| December 31, 2023 | 45.10M |
| September 30, 2023 | 54.52M |
| June 30, 2023 | 41.49M |
| March 31, 2023 | 34.41M |
| December 31, 2022 | 28.44M |
| September 30, 2022 | 55.78M |
| June 30, 2022 | 28.19M |
| March 31, 2022 | 21.62M |
| December 31, 2021 | 23.40M |
| September 30, 2021 | 14.67M |
| June 30, 2021 | 6.62M |
| March 31, 2021 | 0.914M |
| December 31, 2020 | 50.03M |
| September 30, 2020 | 0.029M |
| June 30, 2020 | 0.029M |
| March 31, 2020 | 0.03M |
| December 31, 2019 | 0.029M |
| September 30, 2019 | 0.23M |
| June 30, 2019 | 0.029M |
| March 31, 2019 | 0.03M |
| December 31, 2018 | 0.029M |
| September 30, 2018 | 0.375M |
| Date | Value |
|---|---|
| June 30, 2018 | 0.029M |
| March 31, 2018 | 0.03M |
| December 31, 2017 | 0.03M |
| September 30, 2017 | 0.029M |
| June 30, 2017 | 0.329M |
| March 31, 2017 | 0.03M |
| December 31, 2016 | 0.03M |
| September 30, 2016 | 0.031M |
| June 30, 2016 | 0.055M |
| March 31, 2016 | 0.057M |
| December 31, 2015 | 0.057M |
| September 30, 2015 | 0.057M |
| June 30, 2015 | 0.059M |
| March 31, 2015 | 0.062M |
| December 31, 2014 | 0.068M |
| September 30, 2014 | 0.072M |
| June 30, 2014 | 0.071M |
| March 31, 2014 | 0.067M |
| December 31, 2013 | 0.712M |
| September 30, 2013 | 0.084M |
| June 30, 2013 | 0.085M |
| March 31, 2013 | 0.088M |
| December 31, 2012 | 0.0862M |
| September 30, 2012 | 0.0874M |
| June 30, 2012 | 0.0885M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.029M
Minimum
Dec 2019
67.77M
Maximum
Sep 2024
29.03M
Average
28.31M
Median
Revenue (Quarterly) Benchmarks
| Edesa Biotech Inc | -- |
| Lexaria Bioscience Corp | 0.084M |
| Xenon Pharmaceuticals Inc | -- |
| ESSA Pharma Inc | -- |
| ImmunoPrecise Antibodies Ltd | 3.842M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 14.35M |
| Total Expenses (Quarterly) | 56.02M |
| EPS Diluted (Quarterly) | 0.10 |
| Enterprise Value | 906.94M |
| Gross Profit Margin (Quarterly) | 91.10% |
| Profit Margin (Quarterly) | 21.17% |
| Earnings Yield | -1.58% |
| Normalized Earnings Yield | -1.098 |